XML 40 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
The Company (Details)
$ in Thousands
1 Months Ended
Sep. 30, 2017
USD ($)
number_country
Apr. 20, 2017
USD ($)
shares
Aug. 31, 2014
member_state
Dec. 31, 2016
USD ($)
Aug. 31, 2015
Long-term debt          
Minimum age of ambulatory patient     5 years    
Number of member states of the European Economic Area | member_state     31    
Number of countries | number_country 25        
Retained earnings (Accumulated deficit) $ (815,378)     $ (735,108)  
Convertible debt | 3.00% Convertible senior notes due 2022          
Long-term debt          
Interest rate         3.00%
Non-collaborative Arrangement Transactions | Marathon Pharmaceuticals, LLC          
Long-term debt          
Cash consideration   $ 75,000      
Equity Interest Issued, number of shares (in shares) | shares   6,683,598      
Numerator for calculation of number of shares of equity interests issued to acquire entity   $ 65,000      
Trading day period   15 days      
Development and regulatory milestone payments which the entity may be obligated to pay   $ 50,000